As states consider taxing opioids, drugmakers push back

April 28, 2018 by Geoff Mulvihill And Kyle Potter

Facing a rising death toll from drug overdoses, state lawmakers across the country are testing a strategy to boost treatment for opioid addicts: Force drug manufacturers and their distributors to pay for it.

Bills introduced in at least 15 states would impose taxes or fees on prescription painkillers. Several of the measures have bipartisan support and would funnel millions of dollars toward treatment and prevention programs.

In Montana, state Sen. Roger Webb, a Republican, sees the approach as a way to hold drugmakers accountable for an overdose epidemic that in 2016 claimed 42,000 lives in the U.S., a record.

"You're creating the problem," he said. "You're going to fix it."

Opioids include prescription painkillers such as Vicodin and OxyContin as well as illegal drugs such as heroin and illicit versions of fentanyl. Public health experts say the crisis started because of overprescribing and aggressive marketing of the drugs that began in the 1990s. The death toll has continued to rise even as prescribing has started to drop.

A Pennsylvania opioid tax bill was introduced in 2015 and a federal version was introduced a year later, but most of the proposals arose during the past year. The majority of them have yet to get very far, with lawmakers facing intense pressure from the to scuttle or soften the legislation.

Drugmakers and distributors argue that it would be wrong to tax prescription drugs, that the cost increases would eventually be absorbed by patients or taxpayers, and that there are other ways to pay for and prevention.

"We have been engaged with states to help move forward comprehensive solutions to this complex public health crisis and in many cases have seen successes," Priscilla VanderVeer , a spokeswoman for Pharmaceutical Research and Manufacturers of America, said in a statement. "However, we do not believe levying a tax on prescribed medicines that meet legitimate medical needs is an appropriate funding mechanism for a state's budget."

Two drug companies that deployed lobbyists—Purdue Pharma and Pfizer—responded to questions with similar statements.

A spokesman for the Healthcare Distribution Alliance, which represents drug distributors, said a tax would mean that cancer patients and those in end-of-life care might not be able to get the prescriptions they need.

The pharmaceutical industry has emphasized that the name-brand drug companies that make up its members already give rebates to states for drugs funded by Medicaid. Those rebates amount to billions of dollars nationwide that states could use to address opioid addiction, the trade group says.

State legislation to tax opioids comes as manufacturers and distributors are defending themselves in hundreds of lawsuits filed by state and local governments seeking damages for the toll the overdose epidemic has taken on communities.

David Humes, whose son died from a in 2012, has been pushing for an opioid tax in Delaware, which did not increase funding for addiction treatment last year as it struggles to balance its budget.

"When you think about the fact that each year more people are dying, if you leave the money the same, you're not keeping up with this public health crisis," he said.

Humes, a board member of the advocacy group AtTAck Addiction, supports legislation that would dedicate opioid tax revenue for addiction services.

The lead sponsor of an opioids tax bill, state Sen. Stephanie Hansen, said told her they already were contributing $500,000 to anti-addiction measures in Delaware, where there were 282 fatal overdoses from all drugs in 2016, a 40 percent increase from the year before.

"My response is, 'That's wonderful, but we're not stopping there,'" said Hansen, a Democrat.

She said if her tax measure had been in place last year, it would have raised more than $9 million.

The drug industry's current spending on anti-addiction programs has been a point of contention in the Minnesota Legislature. There, the overdose rate is lower than most , but opioids still claimed 395 lives in 2016—an increase of 18 percent over the year before.

State Rep. Dave Baker, a Republican whose son died of a heroin overdose after getting started on , said opioid manufacturers and distributors should pay for drug programs separately. He said the rebate—about $250 million in 2016 in Minnesota—is intended to make up for overcharging for drugs in the first place.

Another Republican lawmaker, state Sen. Julie Rosen, said she walked out of a meeting this month with industry representatives, saying they were wasting her time.

"They know that they're spending way too much money on defending their position instead of being part of the solution," she said.

Representatives of the pharmaceutical industry say they have met with Rosen multiple times and are "committed to continue working with her."

Drug companies have a history of digging in to defeat measures that are intended to combat the opioid crisis. A 2016 investigation by The Associated Press and the Center for Public Integrity found makers of opioids and their allies spent $880 million on politics and lobbying from 2006 through 2015.

The industry so far has succeeded in stalling the Minnesota legislation, which would charge opioid manufacturers by the dosage. With the bill facing resistance, Rosen and a Democratic co-sponsor, state Sen. Chris Eaton, said they are considering changing tactics and amending it.

That could include raising the $235 annual licensing fee on opioid manufacturers or requiring drugmakers and distributors to pay $20 million a year based on the proportion of opioids they sell in the state. That approach is based on one adopted earlier this spring as part of the budget in New York—the only state to implement an tax so far.

Eaton, whose daughter died from a heroin overdose in 2007, said her goal is to find a way to create and fund a structure that will ensure addiction treatment is "as routine as treating diabetes or cardiac arrest."

Explore further: Ohio sues five drugmakers over role in opioid crisis

Related Stories

Ohio sues five drugmakers over role in opioid crisis

May 31, 2017
The US state of Ohio on Wednesday sued five major producers of prescription opioid medications, accusing them of lying about the deadly risks the painkillers—at the center of a nationwide addiction crisis—posed to public ...

US surgeon general urges Americans to carry opioid antidote

April 5, 2018
The top US doctor on Thursday urged more Americans to carry naloxone, an antidote to opioid overdose, as the nation grapples with a surge in deaths due to potent prescription painkillers and heroin.

Opioid overdoses in ERs up 30 percent as crisis worsens

March 6, 2018
Emergency rooms saw a big jump in overdoses from opioids last year—the latest evidence the nation's drug crisis is getting worse.

State lawmakers channel grief into fight against opioids

February 21, 2017
In statehouses across the country, lawmakers with loved ones who fell victim to drugs are leading the fight against the nation's deadly opioid-abuse crisis, drawing on tragic personal experience to attack the problem.

Senators target physicians, drug manufacturers in opioid bill

February 28, 2018
A bipartisan group of senators on Tuesday introduced legislation that would waive limits on physicians treating addiction patients and place restrictions on how long a provider could initially prescribe opioids to patients.

Drug overdose deaths increase significantly in past five years

December 16, 2016
Drug overdose deaths have increased by 33 percent in the past five years across the country, with some states seeing jumps of nearly 200 percent.

Recommended for you

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

Less is more when it comes to prescription opioids for hospital patients, study finds

May 14, 2018
In a pilot study published in JAMA Internal Medicine, Yale researchers significantly reduced doses of opioid painkillers given to hospital patients. By delivering the opioids with a shot under the skin or with a pill instead ...

Generic options provide limited savings for expensive drugs

May 7, 2018
Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released today in its May issue.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.